Flunixin Meglumin - CAS 42461-84-7
Catalog number: 42461-84-7
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C14H11F3N2O2.C7H17NO5
Molecular Weight:
491.46
COA:
Inquire
Targets:
COX
Description:
Flunixin is a non-steroidal anti-inflammatory drug (NSAID), analgesic, and antipyretic used in horses, cattle and pigs. It is often formulated as the meglumine salt. In the United States, it is regulated by the U.S. Food and Drug Administration (FDA), and may only be lawfully distributed by order of a licensed veterinarian. There are many trade names for the product, as stated below.
Purity:
>98%
Synonyms:
Flunixin meglumine; Banamine; Flumeglumine; Flunixin-S;
MSDS:
Inquire
InChIKey:
MGCCHNLNRBULBU-WZTVWXICSA-N
InChI:
InChI=1S/C14H11F3N2O2.C7H17NO5/c1-8-10(14(15,16)17)5-2-6-11(8)19-12-9(13(20)21)4-3-7-18-12;1-8-2-4(10)6(12)7(13)5(11)3-9/h2-7H,1H3,(H,18,19)(H,20,21);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1
Canonical SMILES:
CC1=C(C=CC=C1NC2=C(C=CC=N2)C(=O)O)C(F)(F)F.CNCC(C(C(C(CO)O)O)O)O
1.Effects of non-steroidal anti-inflammatory drugs in the maturation and fertilization media on bovine oocytes.
Krogenæs A1, Ropstad E, Hafne AL. Theriogenology. 1993 Nov;40(5):1029-38.
In the present investigation the effects of 2 non-steroidal anti-inflammatory drugs commonly used in veterinary practice, flunixin-meglumin (FM) and phenylbutazone (PB), were studied. These drugs were added to the in vitro maturation medium of bovine oocytes. The effect of FM on in vitro fertilization was also tested. The results indicated that in vitro concentrations corresponding to maximal concentrations of FM in the plasma after therapeutic doses did not influence the in vitro maturation or fertilization rates of oocytes. However, doses higher than physiologic concentrations resulted in significant decreases in oocyte maturation and complete failure of fertilization. Concentrations of PB corresponding to concentrations commonly found in the plasma after therapeutic doses resulted in a significant decrease in the number of matured oocytes.
2.Hepatic effects of flunixin-meglumin in LPS-induced sepsis.
Avila TV1, Bastos Pereira AL, De Oliveira Christoff A, Da Silva Soley B, Queiroz Telles JE, Eler GJ, Bracht A, Roberto Zampronio A, Acco A. Fundam Clin Pharmacol. 2010 Dec;24(6):759-69. doi: 10.1111/j.1472-8206.2009.00804.x.
The aim of this study was to evaluate the actions of the non-steroidal anti-inflammatory drug flunixin-meglumin (FM) on the changes caused by lipopolysaccharide (LPS)-induced sepsis in the rat liver. Eight groups of five adult male Wistar rats were analysed: (1) saline injected (controls), (2) FM treated with 1.1 mg/kg, (3) FM treated with 2.2 mg/kg, (4) LPS-injected (10 mg/kg), (5) LPS-injected with 1.1 mg/kg FM pretreatment, (6) LPS-injected with 2.2 mg/kg FM pretreatment, (7) LPS-injected with 1.1 mg/kg FM post-treatment and (8) LPS-injected with 2.2 mg/kg FM post-treatment. All drugs were intraperitoneally injected. The following parameters were evaluated: plasma levels of hepatic enzymes and urea, hepatic histological characteristics, antioxidant enzymes and several metabolic fluxes. The latter comprised gluconeogenesis, ureagenesis and oxygen consumption. Liver damage in LPS-induced sepsis was characterized by histological changes, increased plasma levels of alanine aminotransferase and aspartate aminotransferase (P < 0.
3.Embryo transfer induces a subclinical endometritis in recipient mares which can be prevented by treatment with non-steroid anti-inflammatory drugs.
Koblischke P1, Kindahl H, Budik S, Aurich J, Palm F, Walter I, Kolodziejek J, Nowotny N, Hoppen HO, Aurich C. Theriogenology. 2008 Oct 15;70(7):1147-58. doi: 10.1016/j.theriogenology.2008.06.037. Epub 2008 Jul 25.
We tested the hypothesis that subclinical endometritis occurs after embryo transfer (ET) in the horse. Recipient mares were treated with meclofenamic acid (M) or flunixin meglumin (F) after ET or were left untreated (n=9 per group). Embryos were re-collected 4 days after transfer. Endometrial biopsies were taken for histology and analysis of cyclooxygenase-2 (COX-2) by immunohistochemistry and for PCR. Bacteriological swabs were collected from the uterus and lavage fluid of donor and recipient mares. Progesterone and prostaglandin F(2alpha) release was analysed in recipient mares after ET. Four days after ET, four embryos were recovered from group M and three from group F and untreated mares, each. The number of polymorph nuclear neutrophils was reduced in treated mares (p<0.05). Expression of mRNA for inflammatory cytokines did not differ between groups. In group M, expression of endometrial prostaglandin-E-synthase was higher than in group F (p<0.
4.Possible active transport mechanism in pharmacokinetics of flunixin-meglumin in rabbits.
Miyazaki Y1, Horii Y, Ikenaga N, Shimoda M, Kokue E. J Vet Med Sci. 2001 Aug;63(8):885-8.
The plasma and urine kinetics of flunixin-meglumin (FNX, 2 mg/kg, i.v.) in rabbits were examined. Unusual pharmacokinetic profiles were obtained, including high binding percentage with plasma protein (> 99%), a short elimination half-life (< 4 hr) and a relatively large Vd-area (0.5 L/kg). These profiles indicate that some active transport mechanisms are involved in FNX disposition. The recovery of FNX from urine was approximately 9 % of the dose within 24 hr following the injection. The estimated renal clearance of the unbound drug nearly corresponded to the renal blood flow rates, indicating that active tubular secretion in the renal re-absorptive tract may be involved in the disposition. The effect of a concomitant administration of pravastatin (PV) on FNX disposition was also examined. PV is a representative substrate of a transporter in human liver cells (OATP-2). After the PV administrations, the Vd-area of FNX and total body clearance markedly decreased, indicating that FNX is actively taken up and metabolized in liver cells by an OATP-2 like transporter.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related COX Products


CAS 22071-15-4 Ketoprofen

Ketoprofen
(CAS: 22071-15-4)

Ketoprofen, (RS)2-(3-benzoylphenyl)-propionic acid (chemical formula C16H14O3) is one of the propionic acid class of nonsteroidal anti-inflammatory drugs (NSAID...

CAS 170569-88-7 Mavacoxib

Mavacoxib
(CAS: 170569-88-7)

Mavacoxib, a pyrazol derivative, has been found to be a COX-2 Inhibitor that could be used in pain and inflammation therapy for dogs.

CAS 322-79-2 Triflusal

Triflusal
(CAS: 322-79-2)

Triflusal irreversibly inhibits the production of thromboxane-B2 in platelets by acetylating cycloxygenase-1.

CAS 74103-06-3 Ketorolac

Ketorolac
(CAS: 74103-06-3)

Ketorolac, a non-selective COX inhibitor, is a non-steroidal anti-inflammatory drug. It shows inhibition of eicosanoid formation in HEL cells (COX-1) and LPS-st...

CAS 141505-32-0 Dexibuprofen lysine

Dexibuprofen lysine
(CAS: 141505-32-0)

Dexibuprofen is a Cyclooxygenase inhibitor originated by Gebro Pharma GmbH. It is a non-steroidal anti-inflammatory drug as the active dextrorotatory enantiomer...

CAS 123663-49-0 Iguratimod

Iguratimod
(CAS: 123663-49-0)

Iguratimod(T-614) is a selective inhibitor of cyclo-oxygenase-2 (COX-2), and inhibits the production of interleukin-1 (IL-1), IL-6, IL-8 and tumour necrosis fac...

FR-188582
(CAS: 189699-82-9)

FR-188582, with anti-inflammatory and ulcerogenic properties, is a highly selective inhibitor of COX-2 with IC50= 0.017 microM.

CAS 13710-19-5 Tolfenamic Acid

Tolfenamic Acid
(CAS: 13710-19-5)

A COX-2 inhibitor with IC50 of 0.2 μM

Chemical Structure

CAS 42461-84-7 Flunixin Meglumin

Quick Inquiry

Verification code

Featured Items